German AMNOG reform fails to hit the mark
This article was originally published in Scrip
Executive Summary
Reform of Germany's early benefit assessments is currently under discussion, but the change floated looks unlikely to solve any of the main issues that are frustrating companies. During a recent debate in the German parliament, industry made little progress on ensuring that rebates remain confidential, and nothing is likely to change on the thorny issue of comparators, said Dr Alexander Natz, secretary general of EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs and Brussels representative for the BPI, which represents small- and medium-sized companies in Germany..
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.